Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients

Hypertension
Wing-Yee SoJuliana C N Chan

Abstract

We assessed the effects of angiotensin-converting enzyme (ACE) inhibition on survival and cardiorenal outcomes in a consecutive cohort of Chinese type 2 diabetic patients with varying degree of albuminuria, ranging from normoalbuminuria to macroalbuminuria. A total of 3773 consecutive Chinese type 2 diabetic patients were followed prospectively for a mean period of 35.8 months. Clinical end points included all-cause mortality, with cardiovascular end point defined as first hospitalization because of ischemic heart disease, congestive heart failure, revascularization procedures, or cerebrovascular accident as well as renal end point defined as dialysis, doubling of baseline plasma creatinine, or plasma creatinine > or =500 micromol/L. The use of ACE inhibitor was 26.3% in normoalbuminuric (NA), 70.1% in microalbuminuric (MI), and 82.6% in macroalbuminuric (MA) groups. Albuminuria was a major predictor for all-cause mortality with 4-fold difference between NA and MA patients. The 7-year cumulative mortality rate was 7.1%, 10.8%, and 21.7% in the NA, MI, and MA groups, respectively. The use of ACE inhibition was associated with significant reduction of mortality (hazard ratio 0.41 and 95% confidence interval, 0.29, 0.58) in the en...Continue Reading

References

Mar 1, 1985·Diabetes Care·M Laakso, K Pyörälä
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Oct 26, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D C Felmeden, G Y Lip
Jul 30, 2003·Circulation·Peter M OkinUNKNOWN Losartan Intervention for Endpoint reduction in hypertension Study Investigations

❮ Previous
Next ❯

Citations

May 19, 2011·International Journal of Behavioral Medicine·Lal B RawalBrian Oldenburg
Jan 15, 2014·Diabetes Research and Clinical Practice·Juliana C N ChanJonathan Shaw
Apr 9, 2009·Nature Reviews. Cardiology·Varun AgrawalPeter A McCullough
Oct 18, 2008·Diabetes Research and Clinical Practice·Peter C Y TongJuliana C N Chan
Jul 28, 2006·Diabetes/metabolism Research and Reviews·Xilin YangJuliana C N Chan
Nov 10, 2007·Diabetes/metabolism Research and Reviews·Wing Yee SoJuliana C N Chan
Sep 23, 2014·International Journal of Clinical Practice·D Ramírez-PradoV F Gil-Guillén
Nov 26, 2013·Journal of the American College of Cardiology·Miklos Z MolnarCsaba P Kovesdy
Jan 1, 2015·Diabetes Research and Clinical Practice·Juliana C N ChanUNKNOWN JADE Collaborative Study Group
Jun 10, 2011·Current Cardiovascular Risk Reports·Juliana C N ChanXilin Yang
Feb 17, 2006·Current Opinion in Nephrology and Hypertension·Yiming Z Lit, Timothy Meyer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.